Alembic : Pharmaceuticals Q3 Net Profit up 38% to Rs 234 crores

Vadodara - Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st December 2019.

Financial Highlights

Revenue for the quarter up 19% to Rs 1209 crores from Rs. 1018 crores

Net Profit for the quarter up 38% to Rs 234 crores from Rs 170 crores

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said 'It was a good quarter for the company led by strong growth in the Intemational Markets. We launched 7 products in the US market during the quarter.'

Operational Highlights

International Business

International formulations grew 48% to Rs 664 crores in the quarter.

US Generics grew 61 % to Rs 515 crores in the quarter.

Ex-US Sales grew 15% to Rs 149 crores in the quarter.

8 ANDA approvals received during the quarter and total tally stand at 110.

6 ANDA filings during the quarter; Cumulative ANDA filings at 176

India Formulations Business

The India formulations business was Rs 368 crores for the quarter as against Rs 365 crores last year.

API Business

The API business grew 2% to Rs 553 crores as against Rs 540 crores.

2 DMF were filled in the quarter

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Contact:

Ajay Kumar Desai

Tel: [phone]

Email: [e-mail]

(C) 2020 Electronic News Publishing, source ENP Newswire